RO7248824 for Angelman Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests an experimental treatment called RO7248824 for Angelman Syndrome, a genetic disorder affecting the nervous system. Researchers aim to assess the safety and tolerability of this treatment and understand its behavior in the body. Participants will receive the treatment through an intrathecal injection (into the spine). The trial includes different age-based groups, specifically targeting children aged 1 to 12 years with a confirmed diagnosis of Angelman Syndrome. Those with stable medical status who can undergo procedures like blood draws and lumbar punctures (spinal taps) may be suitable candidates for this trial. As a Phase 1 trial, the study focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial requires that certain medications be stable for a period before joining. Sleep medications must be stable for 4 weeks, epilepsy medications for 12 weeks, and psychotropic medications for 4 weeks before screening. Antiplatelet or anticoagulant therapy should not be used for 2 weeks prior to screening.
Is there any evidence suggesting that RO7248824 is likely to be safe for humans?
Research has shown that early safety results for RO7248824, a treatment for Angelman Syndrome, are acceptable. Studies have found that children tolerate this drug well when administered directly into the spinal fluid. Although specific side effects remain limited, no major safety issues have been reported so far. The study is still in an early phase, so researchers are still gathering initial safety data. For those considering joining a trial, this indicates some evidence of general safety, but further research is needed for confirmation.12345
Why do researchers think this study treatment might be promising for Angelman Syndrome?
Researchers are excited about RO7248824 for Angelman Syndrome because it offers a novel approach compared to traditional therapies, which often focus on managing symptoms with medications like anticonvulsants and behavioral therapies. RO7248824 works by targeting the root cause of Angelman Syndrome, potentially addressing the underlying genetic issues rather than just alleviating symptoms. This treatment utilizes a unique mechanism of action, which could lead to more effective and long-lasting improvements, offering hope for significant advancements in managing this condition.
What evidence suggests that RO7248824 might be an effective treatment for Angelman Syndrome?
Researchers are investigating RO7248824 as a potential treatment for Angelman syndrome due to its focused method. This treatment delivers small pieces of genetic material, called antisense oligonucleotides (ASOs), directly into the spinal fluid to help adjust gene function. The goal is to address the genetic issues causing Angelman syndrome and potentially improve symptoms. Earlier studies have shown that targeting the specific gene can have positive effects, prompting further exploration of this approach. Data collection on its effectiveness in people is ongoing, making participation in trials crucial for understanding its potential. Participants in this trial will receive RO7248824 in various cohorts to evaluate its effectiveness and safety across different age groups.12367
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This trial is for children with Angelman Syndrome (AS) aged 1 to 12 years who can undergo procedures under sedation or anesthesia. They must have a confirmed clinical diagnosis of AS, be able to tolerate blood draws, and have a caregiver willing to comply with study requirements. Participants should not be pregnant or breastfeeding and must meet certain contraceptive requirements.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Multiple ascending dose (MAD) phase where participants receive RO7248824 intrathecally
Long-term extension (LTE)
Participants continue to receive RO7248824 to assess long-term safety and efficacy
Open-label extension (OOE)
Participants in the LTE part of the study will be given the opportunity to participate in the OOE part
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- RO7248824
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University